Tonix Pharmaceuticals Holding Corp. - TNXP
About Gravity Analytica
Recent News
- 09.17.2025 - Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
- 09.17.2025 - Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
- 09.10.2025 - September 2025 Investor Deck
- 09.08.2025 - Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025
- 09.08.2025 - Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025
- 08.28.2025 - Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025
- 08.28.2025 - Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025
- 08.18.2025 - Tonix Pharmaceuticals: U.S. FDA-Approval of Tonmya™
- 08.15.2025 - Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia
- 08.15.2025 - Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia
Recent Filings
- 09.17.2025 - 8-K Current report
- 09.04.2025 - EFFECT Notice of Effectiveness
- 09.04.2025 - S-3/A Registration statement under Securities Act of 1933
- 08.21.2025 - 4 Statement of changes in beneficial ownership of securities
- 08.20.2025 - 4 Statement of changes in beneficial ownership of securities
- 08.18.2025 - 8-K Current report
- 08.15.2025 - 8-K Current report
- 08.11.2025 - 8-K Current report